|
| Press Releases |
|
 |
|
| Wednesday, March 23, 2022 |
|
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
| Monday, February 21, 2022 |
|
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
| Monday, October 5, 2020 |
|
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
| Friday, September 18, 2020 |
|
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
| Friday, July 31, 2020 |
|
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
| Wednesday, June 24, 2020 |
|
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
| Wednesday, June 17, 2020 |
|
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
| Monday, June 1, 2020 |
|
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
| Friday, April 24, 2020 |
|
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
| Wednesday, March 18, 2020 |
|
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CITIC Telecom CPC Wins Two Awards, Celebrating 'Innovation Never Stops' for 25 Years, recognizing Cybersecurity & Innovation Excellence
Feb 9, 2026 13:28 HKT/SGT
|
|
|
中信國際電訊CPC榮獲兩大獎項 慶祝創新不斷廿五載 彰顯網絡安全與持續創新實力
Feb 9, 2026 13:11 HKT/SGT
|
|
|
JCB Announces Collaboration with Resorts World Sentosa in Singapore
Feb 9, 2026 14:00 JST
|
|
|
中信国际电讯CPC荣获两大奖项 庆祝创新不断廿五载 彰显网络安全与持续创新实力
Feb 9, 2026 12:48 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Feb 9, 2026 11:00 JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30: JST
|
|
|
playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group
Feb 8, 2026 23:30 HKT/SGT
|
|
|
Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.
Feb 7, 2026 05:45 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
